Patents-Review.com
ClassID:

20921 ⎘

A61K38/1719 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals Muscle proteins, e.g. myosin or actin

Recent Application in this class:
#1
20260131032
2026-05-14

ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF B-SARCOGLYCAN AND THE TREATMENT OF MUSCULAR DYSTROPHY

 #2
20260091139
2026-04-02

TREATMENT OF CARDIOMYOPATHY WITH AAV GENE THERAPY VECTORS

 #3
20260061074
2026-03-05

GENETIC CONSTRUCTS FOR GENE EDITING

 #4
20260027235
2026-01-29

ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY

 #5
20260007773
2026-01-08

OCULAR VECTORS AND USES THEREOF

 #6
20250387516
2025-12-25

MATERIALS AND METHODS FOR MODIFYING EXPRESSION OF MYOSIN HEAVY CHAIN GENES

 #7
20250375489
2025-12-11

Combination Therapy for Treatment of Muscle Loss Due to Obesity Treatments

 #8
20250369016
2025-12-04

MUSCLE TROPIC RAAV

 #9
20250288699
2025-09-18

SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS VECTOR AND ITS USE IN TREATMENT OF MUSCULAR DYSTROPHY

 #10
20250163469
2025-05-22

ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOF

 #11
20250161490
2025-05-22

ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY

 #12
20250144243
2025-05-08

AAV CAPSIDS FOR IMPROVED HEART TRANSDUCTION AND DETARGETING OF LIVER

 #13
20250121093
2025-04-17

LENTIVIRAL GENE THERAPY RESCUES FUNCTION IN A MOUSE MODEL OF USHER 1B

 #14
20250108134
2025-04-03

CIRCULAR RNA VACCINES AND METHODS OF USE THEREOF

 #15
20250099620
2025-03-27

GENE THERAPY COMPOSITION AND TREATMENT FOR DYSTROPHIN-RELATED CARDIOMYOPATHY

 #16
20250092422
2025-03-20

CARDIAC CELL REPROGRAMMING WITH MYOCARDIN AND ASCL1

 #17
20250051411
2025-02-13

COMPOSITIONS AND METHODS FOR USING ACTIN-BASED PEPTIDES TO MODULATE CELLULAR BIOACTIVITY AND CELLULAR SUSCEPTIBILITY TO INTRACELLULAR PATHOGENS

 #18
20250041452
2025-02-06

METHODS AND COMPOSITIONS FOR TREATING MYBPC3 RELATED HYPERTROPHIC CARDIOMYOPATHY WITH A VIRAL VECTOR

 #19
20250041450
2025-02-06

ADENO-ASSOCIATED VIRUS PARTICLES AND METHODS OF USE THEREOF

 #20
20240409955
2024-12-12

AUF1 COMBINATION THERAPIES FOR TREATMENT OF MUSCLE DEGENERATIVE DISEASE

 #21
20240390508
2024-11-28

HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE

 #22
20240366604
2024-11-07

SELECTIVE INHIBITORS OF ROCK2 FOR THE TREATMENT OF MUSCULAR DYSTROPHY

 #23
20240360452
2024-10-31

METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53

 #24
20240216530
2024-07-04

Compositions and Methods for Treating Skeletal Muscle Disease

 #25
20240200066
2024-06-20

PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY

 #26
20240108687
2024-04-04

COMPOSITIONS AND METHODS FOR USING COMBINATIONS OF ACTIN-BASED PEPTIDES TO MODULATE CELLULAR BIOACTIVITY

 #27
20240052369
2024-02-15

Cardiac cell reprogramming with myocardin and ASCL1

 #28
20230414711
2023-12-28

THERAPEUTICS TARGETING TRANSFORMING GROWTH FACTOR BETA FAMILY SIGNALING

 #29
20230330264
2023-10-19

COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS

 #30
20230279435
2023-09-07

Adeno-associated virus variant capsids and methods of use thereof

 #31
20230241252
2023-08-03

ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF B-SARCOGLYCAN AND THE TREATMENT OF MUSCULAR DYSTROPHY

 #32
20230241248
2023-08-03

METHODS OF TREATING DUCHENNE MUSCULAR DYSTROPHY USING AAV MINI-DYSTROPHIN GENE THERAPY

 #33
20230181687
2023-06-15

Methods and Compositions for Treatment of Age-Related Dysfunction

 #34
20230173101
2023-06-08

ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY

 #35
20230151362
2023-05-18

METHODS AND MEANS FOR EFFICIENT DKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-MRNA

 #36
20230139985
2023-05-04

Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy

 #37
20230108316
2023-04-06

METHODS FOR REHABILITATING HEART FAILURE USING GENE THERAPY

 #38
20230053219
2023-02-16

COMPOSITIONS AND METHODS RELATING TO MYOMAKER-INDUCED MUSCLE CELL FUSION

 #39
20230040544
2023-02-09

COMPOSITIONS AND METHODS FOR RESTORING AND MAINTAINING THE DYSTROPHIN-ASSOCIATED PROTEIN COMPLEX (DAPC)

 #40
20230001015
2023-01-05

Adeno-Associated Virus Vector Delivery of Microrna-29 to Treat Muscular Dystrophy

 #41
20220347168
2022-11-03

LUNG TARGETED ANTICANCER THERAPIES WITH LIPOSOMAL ANNAMYCIN

 #42
20220340629
2022-10-27

Myosin Derived Peptides and Related Compounds with Anticoagulant Activities

 #43
20220280652
2022-09-08

NON-VIRAL IMMUNO-TARGETING

 #44
20220251145
2022-08-11

Adeno-associated virus variant capsids and methods of use thereof

 #45
20220080028
2022-03-17

Methods for Generation of Cell-derived Microfilament Network

 #46
20220062380
2022-03-03

Compositions, Methods and Uses of a Teneurin C-Terminal Associated Peptide-1 (TCAP-1) for Treating Opioid Addiction

 #47
20220023384
2022-01-27

MYBPC3 POLYPEPTIDES AND USES THEREOF

 #48
20210380643
2021-12-09

Adeno-associated virus variant capsids and methods of use thereof

 #49
20210267893
2021-09-02

Artificial exosome composition and related methods

 #50
20210261635
2021-08-26

COMPOSITIONS AND METHODS FOR USING ACTIN-BASED PEPTIDES TO MODULATE CELLULAR BIOACTIVITY AND CELLULAR SUSCEPTIBILITY TO INTRACELLULAR PATHOGENS

 #51
20210207170
2021-07-08

Cardiac cell reprogramming with myocardin and ASCL1

 #52
20210139904
2021-05-13

METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53

 #53
20210139550
2021-05-13

HINGES 1 AND/OR 4 MODIFIED DYSTROPHINS FOR DYSTROPHINOPATHY THERAPY

 #54
20210038687
2021-02-11

Compositions and methods relating to a C-terminal peptide of troponin i with activity as a myofilament CA2+ desensitizer

 #55
20210032659
2021-02-04

Cardiac cell reprogramming with myocardin and ASCL1

 #56
20200405810
2020-12-31

Efficient systemic treatment of dystrophic muscle pathologies

 #57
20200390856
2020-12-17

METHODS OF TREATING AUTOIMMUNE DISEASE

 #58
20200360491
2020-11-19

TREATMENT OF LYSOSOMAL STORAGE DISEASE IN THE EYE THROUGH ADMINISTRATION OF AAVS EXPRESSING TPP1

 #59
20200239886
2020-07-30

Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA

 #60
20200237864
2020-07-30

METHODS AND COMPOSITIONS FOR TREATING FIBROTIC INTERSTITIAL LUNG DISEASE

 #61
20200138904
2020-05-07

Methods for generation of cell-derived microfilament network

 #62
20200108119
2020-04-09

METHODS TO TREAT ALLERGIC CONDITIONS

 #63
20190358294
2019-11-28

Compositions and methods relating to myomaker-induced muscle cell fusion

 #64
20190343767
2019-11-14

Artificial exosome composition and related methods

 #65
20190307899
2019-10-10

Junctophilin-2 fragments and uses therefor

 #66
20190290781
2019-09-26

Methods and Compositions for Treating Dystroglycanopathy Disorders

 #67
20190224362
2019-07-25

Antimicrobial biopolymer compositions, methods of synthesis, and applications of use

 #68
20190191676
2019-06-27

Use of C1q/TNF-related protein-1 (CTRP1) to treat fatty liver disease

 #69
20190177725
2019-06-13

METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA

 #70
20190167762
2019-06-06

Efficient systemic treatment of dystrophic muscle pathologies

 #71
20190119679
2019-04-25

METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA

 #72
20190117795
2019-04-25

Adeno-associated virus vector delivery of microrna-29 to treat muscular dystrophy

 #73
20190112604
2019-04-18

METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA

 #74
20190100754
2019-04-04

Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53

 #75
20190070301
2019-03-07

Activated polyoxazolines and conjugates and compositions comprising the same

 #76
20190060489
2019-02-28

Adeno-associated virus vector delivery of microRNA-29 and micro-dystrophin to treat muscular dystrophy

 #77
20190055581
2019-02-21

Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy

 #78
20180362623
2018-12-20

Methods and compositions for promoting thermogenic potential

 #79
20180022793
2018-01-25

CHEMOREPULSION OF CELLS

 #80
20180015143
2018-01-18

Methods to treat allergic conditions with PIM1 kinase inhibitor

 #81
20180002390
2018-01-04

Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens

 #82
20170368199
2017-12-28

Compositions for treating dystroglycanopathy disorders

 #83
20170349640
2017-12-07

Microdystrophin peptides and methods for treating muscular dystrophy using the same

 #84
20170175135
2017-06-22

Virus Purification

 #85
20170157213
2017-06-08

Efficient systemic treatment of dystrophic muscle pathologies

 #86
20170073702
2017-03-16

Virus purification

 #87
20160304904
2016-10-20

Directed evolution and in vivo panning of virus vectors

 #88
20160263217
2016-09-15

PROTEIN-SPECIFIC FORMULATIONS

 #89
20160228506
2016-08-11

Compositions and Formulations for Prevention and Reduction of Tumorigenesis, Cancer Cell Proliferation and Invasion, and Methods of Production and Use Thereof in Cancer Treatment

 #90
20160136240
2016-05-19

Compositions and methods relating to myomaker-induced muscle cell fusion

 #91
20150190526
2015-07-09

Activated Polyoxazolines and Conjugates and Compositions Comprising the Same

 #92
20150166996
2015-06-18

Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene

 #93
20150118201
2015-04-30

Directed evolution and in vitro panning of virus vectors

 #94
20150073037
2015-03-12

Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA

 #95
20140377310
2014-12-25

METHODS TO TREAT ALLERGIC CONDITIONS

 #96
20140363496
2014-12-11

Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors

 #97
20140234274
2014-08-21

Directed evolution and in vitro panning of virus vectors

 #98
20140234255
2014-08-21

Microdystrophin peptides and methods for treating muscular dystrophy using the same

 #99
20140227281
2014-08-14

Methods of Treating Herpesvirus Infections

 #100
20140038906
2014-02-06

Therapeutic and diagnostic methods involving biglycan and utrophin

 #101
20130345140
2013-12-26

Basement Membrane Compositions and Applications Thereof

 #102
20130345135
2013-12-26

Inhibition of MyBP-C binding to myosin as a treatment for heart failure

 #103
20130136729
2013-05-30

COMPOSITIONS AND METHODS FOR TARGETING AND TREATING DISEASES AND INJURIES USING ADENO-ASSOCIATED VIRUS VECTORS

 #104
20130115589
2013-05-09

Pharmaceutical Composition for Treatment and Prevention of Herpes Virus Infections

 #105
20120114663
2012-05-10

Methods to treat allergic conditions

 #106
20120022134
2012-01-26

Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA

 #107
20110294753
2011-12-01

Means and methods for counteracting muscle disorders

 #108
20110263682
2011-10-27

METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53

 #109
20110104120
2011-05-05

Directed evolution and in vivo panning of virus vectors

 #110
20100310621
2010-12-09

Controlled Iodine Release Particle Micro-Biocide

 #111
20100203087
2010-08-12

Chemorepulsion of cells

 #112
20080213319
2008-09-04

CHEMOREPULSION OF CELLS

 #113
20080032929
2008-02-07

N-terminal truncation of cardiac troponin subunits and their roles in cardiovascular disease